Merz Pharmaceuticals announced that the FDA has approved Xeomin (incobotulinumtoxinA) for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients and blepharospasm in adults previously treated with onabotulinumtoxinA.

Xeomin will be available in late September 2010 in 50-unit and 100-unit vials.

For more information call (888) MERZ-USA or visit www.merzusa.com.